OncoMatch/Clinical Trials/NCT06262321
Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
Is NCT06262321 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for stage 4 nsclc.
Patients with metastatic non small cell lung cancer with high risk location or size are treated with prophylactic radiation therapy in conjunction with standard of care systemic therapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: EGFR wild-type
Required: ROS1 wild-type
Disease stage
Required: Stage T1-4(OR TX)N0-3M1A-C, STAGE IV, METASTATIC RECURRENCE OF PRIMARY STAGE I-III NSCLC (AJCC 8th edition)
Metastatic disease required
T1-4(or Tx)N0-3M1a-c, Stage IV disease (using the 8th edition of the AJCC staging manual) or metastatic recurrence of primary Stage I-III NSCLC that had been treated with curative intent therapy
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Exception: no prior thoracic radiotherapy
Prior radiation therapy to the thoracic region
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Rochester · Rochester, New York
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06262321 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ROS1?
Yes, ROS1 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage T1-4(OR TX)N0-3M1A-C or STAGE IV or METASTATIC RECURRENCE OF PRIMARY STAGE I-III NSCLC is required (metastatic disease required).
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages